Eli Lilly director acquires 9.336 deferred stock units in 2025

Eli Lilly and Company director J. Erik Fyrwald elected to receive 9.336 stock units tied to Eli Lilly common stock on 12/15/2025 instead of cash compensation.

Accepted by SEC EDGAR 12/16/2025 - 04:42 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Eli Lilly and Company director J. Erik Fyrwald elected to receive 9.336 stock units tied to Eli Lilly common stock on 12/15/2025 instead of cash compensation. The units were valued at $1,062.19 each under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after his separation from service.

After this transaction, Fyrwald beneficially owns 75,101.227 shares of Eli Lilly common stock in direct holdings.

Insider Trade Summary

Grant/Award: 9.336 shares

Grant/Award 1 txn

Insider Fyrwald J Erik

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9.336	$1,062.19	$10K

Holdings After Transaction: Common Stock — 75,101.227 shares (Direct)

Holdings Before and After: Common Stock, 75,091.891 to 75,101.227 shares (Direct)

Footnotes (1)

1. F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Eli Lilly (LLY) report for J. Erik Fyrwald?

On 12/15/2025, Eli Lilly director J. Erik Fyrwald acquired 9.336 stock units linked to Eli Lilly common stock by electing to defer cash compensation.

How many Eli Lilly shares does J. Erik Fyrwald own after this transaction?

Following the reported transaction, J. Erik Fyrwald beneficially owns 75,101.227 shares of Eli Lilly common stock in direct holdings.

At what value were the deferred Eli Lilly stock units recorded?

The 9.336 stock units reported for J. Erik Fyrwald were recorded at a price of $1,062.19 per share of Eli Lilly common stock.

What is the Lilly Directors' Deferral Plan mentioned for Eli Lilly (LLY)?

The filing explains that the shares acquired have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after the director's separation from service.

What is J. Erik Fyrwald’s relationship to Eli Lilly (LLY)?

The report identifies J. Erik Fyrwald as a director of Eli Lilly & Co. He is not listed as a 10% owner in this filing.

Is this Eli Lilly (LLY) filing submitted by more than one reporting person?

No. The document indicates that the form is filed by one reporting person, covering the holdings and transaction of J. Erik Fyrwald.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fyrwald J Erik

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		A		9.336(1)	A	$1,062.19	75,101.227	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Remarks:

	/s/ Jonathan Groff for J. Erik Fyrwald, pursuant to authorization on file	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.